Suresh Doddapaneni
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Suresh Doddapaneni has a total of 31 co-authors. Here are the top co-authors by number of shared publications:
- Hao Zhu
Office of Clinical Pharmacology Office of Translational Sciences, Center for Drug Evaluation and Research US Food and Drug Administration Silver Spring MD USA
2 shared publications - Raj Nair
Division of Rheumatology and Transplant Medicine, Office of Immunology and Inflammation, Office of New Drug, Center for Drug Evaluation and Research Food and Drug Administration Silver Spring Maryland USA
2 shared publications - Alana Chen
Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research Food and Drug Administration Silver Spring Maryland USA
1 shared publication - Amit Golding
Division of Rheumatology and Transplant Medicine, Office of Immunology and Inflammation, Office of New Drug, Center for Drug Evaluation and Research Food and Drug Administration Silver Spring Maryland USA
1 shared publication - Anjali Iyer
Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research Food and Drug Administration Silver Spring Maryland USA
1 shared publication - Anuradha Ramamoorthy
Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research Food and Drug Administration Silver Spring Maryland USA
1 shared publication
Latest Publications
- Open Access
- 25 July 2026
- Published by Wiley in Clinical and Translational Science
- Vol. 19 (8) , e70679
Human Radiolabeled Mass Balance Studies Supporting New Drugs Approved by FDA Between 2019 and 2023
- 25 July 2026
- Published by Wiley in Clinical and Translational Science
- Vol. 19 (8) , e70679
Open AccessHuman Radiolabeled Mass Balance Studies Supporting New Drugs Approved by FDA Between 2019 and 2023
- 16 October 2024
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 117 (2) , 475-484
Model‐Informed Drug Development‐Based Approval of Intravenous Secukinumab for the Treatment of Adult Patients with Active Psoriatic Arthritis, Active Ankylosing Spondylitis, and Active Non‐Radiographic Axial Spondyloarthritis
On October 6, 2023, the US Food and Drug Administration (FDA) approved an intravenous (IV) formulation and dosage of Cosentyx® (secukinumab), for the treatment of adult patients with active psoriatic arthritis (PsA), active ankylosing spondylitis (AS), and active non‐radiographic axial spondyloarthritis (nr‐axSpA) with objective signs of inflammation. Clinical pharmacokinetics (PK), efficacy, and short‐term placebo‐controlled safety data were available from clinical studies (NCT04156620 and NCT04209205) with the to‐be‐marketed IV formulation using a maintenance dosage 3 mg/kg every 4 weeks (q4w), which was different from the dose approved (1.75 mg/kg q4w). The IV dosage of 3 mg/kg utilized in these two trials resulted in exposures (Cmax,ss) significantly higher than those for the approved subcutaneous (SC) regimens. Further, there is limited long‐term safety information available for this 3 mg/kg q4w IV dose. To address this important limitation, a model‐informed drug development (MIDD) approach was employed to leverage available clinical PK, efficacy, and safety data from the secukinumab development program to identify a maintenance IV dosing regimen, 1.75 mg/kg IV q4w, that better approximated the relevant SC secukinumab exposures for which efficacy and safety have been established. The MIDD analyses were used to support approval of this IV dosing regimen not directly studied in the indications sought for licensure, PsA, AS, and nr‐AxSpA.
- 16 October 2024
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 117 (2) , 475-484
Model‐Informed Drug Development‐Based Approval of Intravenous Secukinumab for the Treatment of Adult Patients with Active Psoriatic Arthritis, Active Ankylosing Spondylitis, and Active Non‐Radiographic Axial Spondyloarthritis
On October 6, 2023, the US Food and Drug Administration (FDA) approved an intravenous (IV) formulation and dosage of Cosentyx® (secukinumab), for the treatment of adult patients with active psoriatic arthritis (PsA), active ankylosing spondylitis (AS), and active non‐radiographic axial spondyloarthritis (nr‐axSpA) with objective signs of inflammation. Clinical pharmacokinetics (PK), efficacy, and short‐term placebo‐controlled safety data were available from clinical studies (NCT04156620 and NCT04209205) with the to‐be‐marketed IV formulation using a maintenance dosage 3 mg/kg every 4 weeks (q4w), which was different from the dose approved (1.75 mg/kg q4w). The IV dosage of 3 mg/kg utilized in these two trials resulted in exposures (Cmax,ss) significantly higher than those for the approved subcutaneous (SC) regimens. Further, there is limited long‐term safety information available for this 3 mg/kg q4w IV dose. To address this important limitation, a model‐informed drug development (MIDD) approach was employed to leverage available clinical PK, efficacy, and safety data from the secukinumab development program to identify a maintenance IV dosing regimen, 1.75 mg/kg IV q4w, that better approximated the relevant SC secukinumab exposures for which efficacy and safety have been established. The MIDD analyses were used to support approval of this IV dosing regimen not directly studied in the indications sought for licensure, PsA, AS, and nr‐AxSpA.
- Open Access
- 13 February 2024
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 115 (4) , 890-895
Using Machine Learning to Determine a Suitable Patient Population for Anakinra for the Treatment of COVID‐19 Under the Emergency Use Authorization
A randomized, double‐blind, placebo‐controlled study (SAVEMORE trial) provided data to support an Emergency Use Authorization (EUA) of anakinra in hospitalized adults with positive results of direct severe acute respiratory syndrome‐coronavirus 2 viral testing with pneumonia requiring supplemental oxygen (low‐ or high‐flow oxygen) who are at risk of progressing to severe respiratory failure and likely to have an elevated plasma soluble urokinase plasminogen activator receptor (suPAR). Currently, the suPAR assay is not commercially available in the United States. An alternative method was needed to identify patients that best reflect the population in the clinical trial selected based on suPAR level ≥ 6 ng/mL at baseline. A machine learning approach based on data from the SAVEMORE trial was used to develop a scoring rule to identify patients who are likely to have a suPAR level ≥ 6 ng/mL at baseline. External validation of the scoring rule was conducted with data from a different trial (SAVE). This clinical scoring rule with high positive predictive value, high specificity, reasonable sensitivity, and biological relevance is expected to identify patients who are likely to have an elevated suPAR level ≥ 6 ng/mL at baseline. As such, it is included in the EUA to identify patients that fall within the authorized population for whom the known and potential benefits outweigh the known and potential risks of anakinra.
- 13 February 2024
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 115 (4) , 890-895
Open AccessUsing Machine Learning to Determine a Suitable Patient Population for Anakinra for the Treatment of COVID‐19 Under the Emergency Use Authorization
A randomized, double‐blind, placebo‐controlled study (SAVEMORE trial) provided data to support an Emergency Use Authorization (EUA) of anakinra in hospitalized adults with positive results of direct severe acute respiratory syndrome‐coronavirus 2 viral testing with pneumonia requiring supplemental oxygen (low‐ or high‐flow oxygen) who are at risk of progressing to severe respiratory failure and likely to have an elevated plasma soluble urokinase plasminogen activator receptor (suPAR). Currently, the suPAR assay is not commercially available in the United States. An alternative method was needed to identify patients that best reflect the population in the clinical trial selected based on suPAR level ≥ 6 ng/mL at baseline. A machine learning approach based on data from the SAVEMORE trial was used to develop a scoring rule to identify patients who are likely to have a suPAR level ≥ 6 ng/mL at baseline. External validation of the scoring rule was conducted with data from a different trial (SAVE). This clinical scoring rule with high positive predictive value, high specificity, reasonable sensitivity, and biological relevance is expected to identify patients who are likely to have an elevated suPAR level ≥ 6 ng/mL at baseline. As such, it is included in the EUA to identify patients that fall within the authorized population for whom the known and potential benefits outweigh the known and potential risks of anakinra.